

INDEX

A

- Abscess, 600, 601*f*, 602
apocrine sweat gland, 14–16, 15*f*, 17*f*
tuberculosis, metastatic, 661–662, 664, 666
- Acantholytic dermatosis, transient, 112, 113*f*
- Acanthosis nigricans (AN), 82–83, 83*f*
classification, 82
malignant, 82–83, 493, 493*f*–494*f*
- ACD. *See* Allergic contact dermatitis
- ACDRs (adverse cutaneous drug reactions).
See Drug reactions
- ACE (angiotensin-converting enzyme) inhibitors, reactions to, 556
- Acetowhitening, 1015
- Acne keloidalis, 941, 945*f*
- Acne rosacea. *See* Rosacea
- Acne vulgaris, 2–6, 3*f*, 5*f*, 7*f*
acne conglobata, 4
acne fulminans, 4
recalcitrant acne, 4
- Acneform drug eruptions, 548
- Acral lentiginous melanoma (ALM), 295–296, 297*f*
- Acrochordon, 209*f*
- Acrodermatitis continua of Hallopeau, 69
- Acrodermatitis enteropathica, 430–431, 432*f*
- Acrosclerosis, 375*f*
- ACTH-induced pigmentation, 568
- Actinic keratosis, 217, 219, 220*f*
- Actinic prurigo, 230, 234
- Acute febrile neutrophilic dermatosis. *See* Sweet's syndrome
- Acute retroviral syndrome (ARS), 912–915, 915*f*, 915*t*
- AD. *See* Atopic dermatitis
- Addison's disease, 424, 424*f*
- Adult T cell leukemia/lymphoma (ATLL), 532–533, 533*f*–534*f*
- Adverse cutaneous drug reactions (ACDRs).
See Drug reactions
- Albinism, 322–324, 325*f*–326*f*
classification, 322, 323*t*
iris translucency with, 326*f*
ocular, 322, 323*t*, 324
oculocutaneous, 322, 323*t*, 324, 325*f*–326*f*
- Aleppo sore. *See* Leishmaniasis
- Allergic contact dermatitis (ACD), 26–28, 28*f*–29*f*
anogenital, 995, 995*f*
- Allergic cutaneous vasculitis, 381–384, 382*f*–383*f*
- Allergic phytodermatitis (APD), 26–28, 28*f*–29*f*
- Allopurinol, drug reaction to, 554
- ALM (acral lentiginous melanoma), 295–296, 297*f*
- Alopecia
nonscarring, 928–940
alopecia areata, 928–930, 929*f*, 931*f*
alopecia totalis, 928
alopecia universalis, 928, 931*f*
anagen effluvium, 940, 940*f*
androgenetic alopecia, 932–936, 933*f*, 935*f*–936*f*
neoplastica, 482
telogen effluvium, 937–939, 938*t*–939*t*, 939*f*
scarring, 941, 942*f*–945*f*, 942*t*
- α_1 antitrypsin-deficiency panniculitis, 146
- Amiodarone-induced pigmentation, 566, 567*f*
- Amoxicillin drug reaction, 554
- Ampicillin drug reaction, 553*f*, 554
- Amyloidosis, systemic, 334–336, 335*f*, 337*f*
acquired, 334–336, 335*f*, 337*f*
secondary, 334, 336
- AN. *See* Acanthosis nigricans
- Anagen effluvium, 940, 940*f*
- Anaphylaxis and anaphylactoid reactions, 547, 556, 558
- Angioedema and urticaria, 338–344, 339*f*, 341*f*–343*f*, 344*t*, 345*f*
drug reaction, 547, 556–558, 559*f*
urticaria perstans, 393–394, 394*f*
urticarial vasculitis, 393–394, 394*f*
- Angiokeratoma, 183*f*
- Angioma
cherry, 181*f*
spider, 182*f*
- Angiomatous nevus (capillary hemangioma of infancy), 173–174, 174*f*–175*f*
- Angioneurotic edema, 556–558, 559*f*
- Angiotensin-converting enzyme (ACE) inhibitors, reactions to, 556
- Anogenital warts. *See* Human papillomavirus, sexually transmitted
- Antibiotics, reaction to, 556
- Antimalarial-induced pigmentation, 567
- Anus. *See* Genitalia, perineum, and anus, disorders of
- APD (allergic phytodermatitis), 26–28, 28*f*–29*f*

Aphthous ulcer, 976–977, 977f
 Apocrine sweat gland abscess, 14–16, 15f, 17f
 Apocrinities, 14–16, 15f, 17f
 ARS (acute retroviral syndrome), 912–915, 915f, 915t
 Arterial insufficiency, 452–457
 Arterial spider, 182f
 Arthralgia-myalgia syndrome, 377
 Arthropod bites, 820–825, 822f–825f
 Asteatotic dermatitis, 49, 49f
 Atheroembolization, 452–457, 455f–456f
 Atherosclerosis, 452–457, 453f–454f
 Atherosclerosis obliterans (ASO), 453f–455f
 Athlete's foot, 688–690, 689f, 691f–692f
 ATLL (adult T cell leukemia/lymphoma), 532–533, 533f–534f
 Atopic dermatitis (AD), 30–35, 31f–33f, 35f
 anogenital, 996
 epidemiology, 30
 lichenification, 31, 31f, 35f
 management, 34–35
 Atopic eczema, 30–35, 31f–33f, 35f
 Atrophoderma of Pasini and Pierini, 126f
 Auspitz's sign, 1016
 Autoimmune diseases, skin signs of. *See* Immune, autoimmune, and rheumatic diseases, skin signs of
 Autosensitization dermatitis, 44, 44f

B

Bacillary angiomatosis, 646–648, 647f
 Bacterial infections involving the skin, 580–683
 gram-negative infections, 642–653
 bacillary angiomatosis, 646–648, 647f
 Bartonella infection overview, 642, 642t
 cat-scratch disease/fever, 643–644, 645f
 Pseudomonas aeruginosa infections, 652–653
 tularemia, 649–650, 651f
 gram-positive infections associated with toxin production, 620–629
 scarlet fever, 626–628, 627f, 629f
 staphylococcal scalded-skin syndrome (SSSS), 620–622, 621f, 623f
 toxic shock syndrome, 624–626, 625f
 infective endocarditis. *See* Infective endocarditis
 Lyme borreliosis. *See* Lyme borreliosis
 mycobacterial infections, 654–671
 cutaneous nontuberculous infections, 666–671
 cutaneous tuberculosis, 661–666, 663f–665f
 epidemiology, 654
 leprosy. *See* Leprosy

pyodermas, 586–603
 abscess, furuncle, and carbuncle, 600–602, 601f, 603f
 impetigo and ecthyma, 586–590, 587f–589f, 591f
 infectious folliculitis. *See* Infectious folliculitis
 pathogenesis, 586
 sepsis and septic shock, 636–640, 639f, 641f
 epidemiology, 636
 management, 640
 physical examination, 637–638
 soft tissue infections (STIs), 604–619
 cellulitis. *See* Cellulitis
 ecthyma gangrenosum, 604
 erysipelas. *See* Erysipelas
 etiology, 605t–606t
 lymphangitis, 604, 618, 619f
 necrotizing soft tissue infection (NSTI), 604
 superficial cutaneous infections, 580–585
 erythrasma, 580–582, 581f
 intertrigo, 584, 584f–585f
 pitted keratolysis, 582–583, 583f
 therapy (antimicrobial agents), 682t–683t
 Baghdad boil (button). *See* Leishmaniasis
 Bairnsdale ulcer, 668–669, 669f
 Balanoposthitis, 718, 719f
 Baldness. *See* Alopecia
 Barbiturates, drug reactions to, 554
Bartonella infections, 642–648
 bacillary angiomatosis, 646–648, 647f
 cat-scratch disease/fever, 643–644, 645f
 overview, 642, 642t
 Basal cell carcinoma (BCC), 261–265, 261f–265f
 Basal cell nevus syndrome, 266–268, 267f–268f
 Bazin's disease, 395, 396f
 BCC (basal cell carcinoma), 261–265, 261f–265f
 Beau's lines, 968, 972f
 Becker's nevus, 198f
 Bed sore, 474–477, 475f–476f
 Bedbugs, 821, 823f
 Behçet's syndrome/disease, 346–348, 347f–348f
 Benign neoplasms and hyperplasias, 160–209
 Becker's nevus, 198f
 dermatofibroma, 204, 205f
 digital myxoid cyst, 191f
 disorders of blood vessels. *See* Blood vessel disorders
 disorders of melanocytes. *See* Melanocytes, disorders of

- epidermal inclusion cyst, 190*f*
epidermal nevus, 202*f*
epidermoid cyst, 188*f*
hypertrophic scars and keloids, 206–207, 207*f*–208*f*
keratoacanthoma (KA), 196, 197*f*
lipoma, 203*f*
milia, 190*f*
nevus sebaceous, 201*f*
sebaceous hyperplasia, 200*f*
seborrheic keratosis, 192–193, 193*f*–195*f*
skin tag, 209*f*
syringoma, 199*f*
trichilemmal cyst, 189*f*
trichoepithelioma, 199*f*
- Benzodiazepines, drug reactions to, 554
- Berlque dermatitis, 221, 222*f*
- Birthmarks, classification of, 173
- Bites, insect. *See* Insect bites and infestations
- Black dot tinea capitis variant, 700–702, 702*f*–703*f*
- Black flies, 821
- Blennorrhagia, 885–886, 886*f*
- Blennorrhoea, 885–886, 886*f*
- Bleomycin-induced pigmentation, 568
- Blepharophyma, 8
- Blister beetles, 821
- Blood vessel disorders, 173–187
angiokeratoma, 183*f*
capillary hemangioma of infancy (CHI), 173–174, 174*f*–175*f*
capillary/venous/lymphatic (CVL) malformations, 179, 180*f*
cherry angioma, 181*f*
glomus tumor, 186*f*
lymphatic malformation (lymphangioma), 187*f*
port-wine stain, 176, 177*f*–178*f*
pyogenic granuloma, 184, 185*f*
spider angioma, 182*f*
vascular birthmark classification, 173
venous lake, 180*f*
- Blue neuronevus, 166, 167*f*
- Blue nevus, 166, 167*f*
- Blue rubber bleb nevus, 179
- Botfly, 822, 824*f*
- Bouton d'Orléans. *See* Leishmaniasis
- Bowenoid papulosis, 869
- Bowen's disease, 255, 256*f*
- Brazilian pemphigus, 96
- Breast cancer, 480, 481*f*
- Brocq, pseudopelade of, 941, 942*f*–943*f*
- Brunsting-Perry pemphigoid, 101
- Buccal and gingival mucosa, disorders of, 976–979, 977*f*–978*f*
- Bullae, 1011–1012
diabetic, 412, 412*f*
- Bullous diseases, 84–105
with oral manifestations, 980–982, 980*f*–982*f*
- Bullous drug eruptions, 548
- Bullous impetigo, 588, 589*f*
- Bullous pemphigoid, 98–100, 99*f*–100*f*
- Buruli ulcer, 668–669, 669*f*
- Busulfan-induced pigmentation, 568
- ## C
- Calcification, widespread systemic, 417–418, 418*f*
- Calciphylaxis, 417–418, 418*f*
- Calcium channel blockers, reaction to, 556
- Campbell de Morgan spots, 181*f*
- Cancers
epidermal. *See* Epidermal precancers and cancers
nonmelanoma, variation in HIV disease, 924
systemic, skin signs of, 478–495
acanthosis nigricans, malignant, 82–83, 493, 493*f*–494*f*
Cowden's syndrome (multiple hamartoma syndrome), 488, 489*f*
glucagonoma syndrome, 490, 491*f*
metastatic cancer to the skin, 479–483, 480*f*–481*f*, 483*f*
patterns of cutaneous involvement, 479–480, 482
Paget's disease, 484–487, 485*f*, 487*f*
paraneoplastic pemphigus (PNP), 495, 495*f*
Peutz-Jeghers syndrome (PJS), 492, 492*f*
- Candida* leukoplakia, 714–716, 715*f*, 717*f*
- Candidiasis, 708–721
chronic mucocutaneous, 720, 721*f*
classification, 709
cutaneous, 710–713, 710*f*–713*f*
epidemiology, 708
genital, 718–720, 719*f*
management, 709
mucosal, variation in HIV disease, 924
oropharyngeal, 714–716, 715*f*, 717*f*
- Candidosis. *See* Candidiasis
- Canker sore, 976–977, 977*f*
- Capillary hemangioma of infancy (CHI), 173–174, 174*f*–175*f*
- Capillary/venous/lymphatic (CVL) malformations, 179, 180*f*
- Carbamazepine drug reaction, 554
- Carbuncle, 600, 602, 603*f*
- Carcinoma telangiectaticum, 479
- Carotene-induced pigmentation, 568
- Cat-scratch disease/fever, 643–644, 645*f*

- Caterpillars, 821
- Cave disease, 737–738, 739f
- Cavernous hemangioma, 173, 179, 180f
- CDLE (classic chronic discoid lupus erythematosus), 369–370, 371f
- Cellulitis, 604, 606–613, 609f, 611f, 613f
 - epidemiology, 606–607
 - gangrenous, 604, 614–617
 - clostridial soft tissue infections, 616
 - immunocompromised individuals, 617
 - necrotizing fasciitis (NF), 614, 616
 - nonclostridial anaerobic, 616
 - progressive bacterial synergistic gangrene, 616
 - infecting organisms, 607, 610
- Cercarial dermatitis, 848t, 849, 849f
- Chancroid, 901–904
- Chemotherapeutic agents, reaction to, 556
- Cherry angioma, 181f
- CHI (capillary hematoma of infancy), 173–174, 174f–175f
- Chicago disease, 740–742, 741f
- Chickenpox (varicella), 801–804, 803f
- Chigoe, 821
- Chloasma, 327–328, 329f
- Chloroquine-induced pigmentation, 567
- Chlorpromazine-induced pigmentation, 568
- Chromoblastomycosis, 729–730, 730f
- Chromomycosis, 729–730, 730f
- Chronic venous insufficiency (CVI), 462–467, 463f, 465f–466f
- Cicatricial pemphigoid, 101, 101f
- Cicatrizing perifolliculitis, 14
- Clam digger's itch, 848t, 849, 849f
- Clap, 885–886, 886f
- Clark melanocytic nevus (CMN), 272–276, 274t, 275f, 277f
- Classic chronic discoid lupus erythematosus (CDLE), 369–370, 371f
- CLM (cutaneous larva migrans), 844–846, 845f, 845t, 847f
- Clofazimine-induced pigmentation, 566
- Clostridial soft tissue infections, 616
- CMN (Clark melanocytic nevus), 272–276, 274t, 275f, 277f
- CNN (congenital nevomelanocytic nevus), 278–280, 279f, 281f
- Cold sore. *See* Herpes simplex virus
- Collodion baby, 76, 80, 81f
- Common acne (acne vulgaris), 2–6, 3f, 5f, 7f
- Condyloma acuminatum, 986, 986f–987f. *See also* Human papillomavirus, sexually transmitted
- Congenital nevomelanocytic nevus (CNN), 278–280, 279f, 281f
- Consumption, 661
- Contact dermatitis, 18–23, 19f, 21f, 22t, 23f, 23t
 - allergic contact dermatitis, 18–20, 21f, 22, 22t–23t, 23f, 26–28, 28f–29f
 - common contact allergens, 23t
 - irritant contact dermatitis (ICD), 18–20, 19f, 22, 22t, 24–25
 - etiologic agents, 24
 - toxic contact dermatitis of the hands, 20, 21f
- Cowden's syndrome, 488, 489f
- Crab lice (pediculosis pubis), 830–832, 831f–832f
- Cradle cap, 45–48, 46f
- Cranial arteritis, 390–391, 391f–392f
- Creeping eruption. *See* Cutaneous larva migrans
- Creeping verminous dermatitis. *See* Cutaneous larva migrans
- Crest syndrome, 374, 377, 377f
- Crusts, 1013f
- Cryoglobulinemia, 504–506, 505f, 507f
 - classification, 504
- Cryptococcosis, 734–736, 735f
- CTCL. *See* Cutaneous T cell lymphoma
- Cushing's syndrome, 420, 420f
- Cutaneous B cell lymphoma, 543, 543f–544f
- Cutaneous horn, 250, 251f
- Cutaneous larva migrans (CLM), 844–846, 845f, 845t, 847f
- Cutaneous lymphomas and sarcoma. *See* Lymphomas and sarcoma
- Cutaneous melanoma. *See* Melanoma
- Cutaneous necrosis drug reaction, 548–549, 549f
- Cutaneous papilloma, 209f
- Cutaneous T cell lymphoma (CTCL), 535–537, 537f–541f
 - classification, 536t–537t
 - management, 536–537
 - Sézary's syndrome, 535, 537, 542
- CVI (chronic venous insufficiency), 462–467, 463f, 465t–466f
- CVL (capillary/venous/lymphatic) malformations, 179, 180f
- Cyclophosphamide-induced pigmentation, 568
- Cystic acne, 4
- Cysts, 188–191
 - digital myxoid, 191f
 - epidermal, 188f
 - epidermal inclusion, 190f
 - epidermoid, 188f
 - isthmus catagen, 189f
 - miliium, 190f
 - mucous, 191f

pilar, 189*f*
sebaceous, 188*f*
trichilemmal, 189*f*
Cytostatic agents, drug reaction to, 556
Cytosan-induced pigmentation, 568

D

Darier's sign, 514, 515*f*, 1016
Darling's disease, 737–738, 739*f*
Decubitus ulcer, 474–477, 475*f*–476*f*
Deep congenital nevomelanocytic nevus, 278
Deep venous thrombosis, 458, 460, 461*f*
 predisposing factors, 458*t*
Deerfly fever, 649–650, 651*f*
Delhi boil (button). *See* Leishmaniasis
Demodicidosis, 595
Dercum's disease, 203*f*
Dermal melanocytoma, 166, 167*f*
Dermatitis
 asteatotic, 49, 49*f*
 atopic, 30–35, 31*f*–33*f*, 35*f*
 autosensitization, 44, 44*f*
 Berloque, 221, 222*f*
 cercarial, 848*t*, 849, 849*f*
 contact. *See* Contact dermatitis
 eczematous, 18–49
 hands, toxic contact dermatitis of, 20, 21*f*
 lime, 221, 222*f*
 perioral, 12, 13*f*
 periorbital, 13*f*
 radiation. *See* Radiation dermatitis
 seborrheic, 45–48, 46*f*–47*f*
 stasis, 462, 464, 465*f*, 469
Dermatitis herpetiformis (DH), 102–103, 104*f*
Dermatofibroma, 204, 205*f*
Dermatofibrosarcoma protuberans, 545, 545*f*
Dermatoheliosis, 214–219, 215*f*, 218*f*, 220*f*
 solar keratosis, 217, 219, 220*f*
 solar lentigo, 217, 218*f*
Dermatomes, 810*f*–811*f*
Dermatomyositis, 349–351, 350*f*–352*f*
 drug reaction, 548
Dermatophytic folliculitis, 594, 597*f*
Dermatophytoses, 684–707
 classification, 685
 epidemiology, 684–685
 of epidermis, 688–699
 tinea corporis, 696–697, 696*f*–697*f*
 tinea cruris, 694, 695*f*
 tinea facialis, 698–699, 698*f*–699*f*, 707*f*
 tinea incognito, 699, 699*f*
 tinea manuum, 693–694, 693*f*
 tinea pedis, 688–690, 689*f*, 691*f*–692*f*
 of hair, 700–707
 tinea barbae, 706, 706*f*–707*f*
 tinea capitis, 700–704, 701*f*–702*f*, 705*f*
 management of, 686–687
 variation in HIV disease, 924
Dermatosis
 digitate, 109, 110*f*
 ichthyosiform, 70–83
 linear IgA, 105, 105*f*
 papulosa nigra, 194*f*
 pigmented purpuric, 131–133, 132*f*–133*f*
Dermopathy, diabetic, 414, 414*f*
Desert fever, 743–745
Desmoplastic melanoma, 293–294, 294*f*
Desquamation (scaling), 1013*f*
Diabetes mellitus (DM), 411–418
 associated skin diseases, 411*t*
 calciphylaxis, 417–418, 418*f*
 classification, 411
 diabetic bullae, 412, 412*f*
 diabetic dermopathy, 414, 414*f*
 diabetic foot, 413, 413*f*
 diabetic neuropathy, 413, 413*f*
 necrobiosis lipidica, 415–416, 416*f*
Diagnosis, clinical and laboratory aids to,
 1015–1017
 biopsy, 1017
 clinical examination techniques, 1015
 clinical signs and tests, 1016
 microscopic examination, 1016–1017
Diaper dermatitis, 710, 713*f*
Diascopy, 1015
Digital myxoid cyst, 191*f*
Digitate dermatosis, 109, 110*f*
Discoid eczema, 42, 43*f*
Disseminated coccidioidomycosis, 743–744,
 745*f*
Disseminated cryptococcosis, 734–736, 735*f*
Disseminated intravascular coagulation (DIC),
 500–502, 501*f*, 503*f*
DM. *See* Diabetes mellitus
Donovanosis, 905–906, 906*f*
Drug rash with eosinophilia and systemic
 symptoms (DRESS), 564–565, 565*f*
Drug reactions, 546–571
 acneform eruptions, 548
 anaphylaxis and anaphylactoid, 547, 556,
 558
 angioedema, 547, 556–557
 bullous eruptions, 548
 cutaneous necrosis, 548–549, 549*f*
 dermatomyositis-like reactions, 548
 drug hypersensitivity syndrome, 564–565,
 565*f*
 eczematous eruptions, 548
 edema, 556
 erythema multiforme, 547
 erythema nodosum, 548
 erythroderma, 548

exanthematous, 547, 552–555, 553f
 specific drugs, 554
 exfoliative dermatitis, 153t, 156f, 548
 fixed drug eruptions, 547, 560–562, 561f, 563f
 specific drugs, 560
 hypertrichosis, 950, 951f
 immunologically mediated, 550t
 injecting drug use, cutaneous signs of, 570, 571f
 lichen planus, 116t
 lichenoid eruptions, 547
 life-threatening, 546–547
 lupus erythematosus-like syndrome, 548
 management, 550
 overview, 546–549
 pemphigus vulgaris, 96
 photosensitivity, 223–229, 547
 pigmentation reactions, 549, 566–568, 567f, 569f
 specific drugs, 566–568
 pityriasis rosea-like reactions, 548
 porphyria cutanea tarda, 547
 pseudolymphoma, 548
 psoriasiform reactions, 548
 purpura, 547–548
 pustular eruptions, 548
 scleroderma-like reactions, 377, 548
 serum sickness, 547
 Stevens-Johnson syndrome (SJS), 547
 toxic epidermal necrolysis (TEN), 547
 urticaria, 547, 556–558, 559f
 variation in HIV disease, 924
 Drug use, cutaneous signs of, 570, 571f
 Duckhunter's itch. *See* Cutaneous larva migrans
 Dyshidrotic eczematous dermatitis, 39–40, 41f
 Dysmorphic syndrome, 579
 Dysplastic melanocytic nevus, 272–276, 274t, 275f, 277f

E

EB. *See* Epidermolysis bullosa
 Ecthyma, 586–591, 591f
 Ecthyma gangrenosum, 604
 Eczema
 atopic dermatitis, 30–35, 31f–33f, 35f
 craquelé, 49, 49f
 dermatitis, 18–49
 discoid, 42, 43f
 drug reaction, 548
 nummular, 42, 43f
 Edema drug reaction, 556
 EF (eosinophilic folliculitis), 916–918, 917f
 Elephantiasis nostras verrucosa, 469
 En cuirasse metastatic carcinoma, 479–480

Endocrine diseases. *See* Genetic, metabolic, endocrine, and nutritional diseases
 Endothrix tinea capitis, 700–701
 Eosinophilic folliculitis (EF), 916–918, 917f
 EPD (extramammary Paget's disease), 486–487, 487f
 Epidermal cyst, 188f
 Epidermal inclusion cyst, 190f
 Epidermal nevus, 202f
 Epidermal nevus, 202f syndrome, 202f
 Epidermal precancers and cancers, 248–251
 cutaneous horn, 250, 251f
 epithelial precancerous lesions, 248–249
 solar keratosis, 217, 219, 220f
 Epidermodyplasia verruciformis, 762
 Epidermoid cyst, 188f
 Epidermolysis bullosa (EB), 84–90, 85f, 86t, 87f, 88t, 89f, 91f
 dystrophic, 86t, 88, 89f, 91f
 generalized atrophic benign epidermolysis bullosa (GABEB), 86, 86t, 87f
 junctional, 86, 86t, 87f
 simplex, 84, 86t
 Epidermolytic hyperkeratosis, 78, 79f
 Epithelial precancerous lesions, 248–249
 Epithelioid spindle cell-nevus, 168–169, 169f
 Erysipelas, 604, 606–613, 608f
 epidemiology, 606–607
 infecting organisms, 607, 610
 Erysipeloid, 611f
 Erythema induratum, 395, 396f
 Erythema infectiosum, 778–780, 779f–780f
 Erythema multiforme
 drug reaction, 547
 Erythema multiforme syndrome, 136–138, 137f–139f
 distribution, 138f
 major, 136
 maximal variant, 136
 minor, 136
 Erythema nodosum
 drug reaction, 548
 Erythema nodosum syndrome, 144, 145t
 etiology, 145t
 Erythema nuchae, 176
 Erythrasma, 580–582, 581f
 Erythroderma
 in acutely ill patients, 152–154, 153t, 155f–157f
 drugs associated with, 153t
 etiology, 153t
 drug reaction, 153t, 548
 Erythrohepatic protoporphyria, 245–247, 246f–247f
 Erythroplasia, 983, 983f

of Queyrat, 260*f*
Erythropoietic porphyria, 245–247, 246*f*–247*f*
Espundia. *See* Leishmaniasis
Esthiomene, 908
Estrogen-induced pigmentation, 568
European blastomycosis, 734–736, 735*f*
Exanthematous drug reactions, 547, 552–555, 553*f*
 specific drugs, 554
Exanthems, infectious, 766–780
Exfoliative dermatitis drug reaction, 548
Exfoliative erythroderma syndrome, 152–154, 153*t*, 155*f*–157*f*
External genital warts. *See* Human papillomavirus, sexually transmitted
Extramammary Paget's disease (EPD), 486–487, 487*f*

F

Fabry's disease, 183*f*
Factitious syndromes, 578, 578*f*
Familial benign pemphigus, 92, 93*f*
Familial lipoma syndrome, 203*f*
Farmer's skin, 214
Fever blister. *See* Herpes simplex virus
Fibroma, oral, 979
Fibrous nodule, 979
Fifth disease (erythema infectiosum), 778–780, 779*f*–780*f*
Fish tank granuloma, 666–668, 667*f*
Fissured tongue, 975, 975*f*
Fixed drug eruptions, 547, 560–562, 561*f*, 563*f*
 specific drugs, 560
Fleas, 821–822, 822*f*
Flies, 821–822
Focal fibrous hyperplasia, 979
Follicular eczema, 31, 32*f*
Follicular occlusion syndrome, 14
Folliculitis, syphilitic, 595
Folliculitis decalvans, 941, 944*f*
Fordyce, angiokeratoma of, 183*f*
Fournier's gangrene, 616
Fungal infections
 HIV disease, 925
 skin and hair. *See* Skin and hair, fungal infections of
Furuncle, 600, 601*f*, 602, 603*f*

G

GA (granuloma annulare), 120–122, 121*f*
 variants, 120
Gangrenous cellulitis, 604, 614–617
 clostridial soft tissue infections, 616
 immunocompromised individuals, 617

 necrotizing fasciitis (NF), 614, 616
 nonclostridial anaerobic, 616
 progressive bacterial synergistic gangrene, 616
Gas gangrene, 615*t*, 616
GCNN (giant congenital nevocellular nevus), 276, 278, 280, 281*f*
GD (Grover's disease), 112, 113*f*
Genetic, metabolic, endocrine, and nutritional diseases, 406–451
 Addison's disease, 424, 424*f*
 Cushing's syndrome and hypercorticism, 420, 420*f*
 diabetes. *See* Diabetes mellitus
 generalized pruritus without diagnostic skin lesions, 425–427
 Graves' disease and hyperthyroidism, 421, 421*f*
 hereditary hemorrhagic telangiectasia, 419, 419*f*
 hypothyroidism and myxedema, 422–423
 neurofibromatosis (NF), 440–442, 441*f*, 443*f*
 pellagra, 433, 433*f*
 pregnancy, diseases in, 406–410
 pseudoxanthoma elasticum (PXE), 434–436, 435*f*–436*f*
 scurvy, 428–429, 429*f*
 tuberous sclerosis, 437–438, 438*f*–439*f*
 xanthelasma, 445, 446*f*
 xanthomas. *See* Xanthomas
 zinc deficiency and acrodermatitis enteropathica, 430–431, 431*f*–432*f*
Genital herpes, 874–881, 876*f*–879*f*
 epidemiology, 874
 management, 880–881
 pathogenesis, 875
 physical examination, 875
 primary, 875, 876*f*
 progenitalis. *See* Herpes simplex virus recurrent, 875, 877*f*–879*f*
Genital warts. *See* Human papillomavirus, sexually transmitted
Genitalia, perineum, and anus, disorders of, 988–1007
 allergic contact dermatitis (ACD), 995, 995*f*
 atopic dermatitis, 996
 genital lentiginoses, 988, 989*f*
 lichen planus (LP), 993, 993*f*–994*f*
 lichen sclerosus (LS), 998, 999*f*
 lichen simplex chronicus, 996, 996*f*
 precancerous and cancerous lesions, 1000–1007
 HPV-induced squamous intraepithelial lesion and squamous cell carcinoma in situ, 1002, 1003*f*

invasive anogenital squamous cell carcinoma, 1004, 1004f–1005f
malignant melanoma of the anogenital region, 1006, 1006f–1007f
squamous cell carcinoma in situ (SCC), 1000, 1000f–1001f
pruritus ani, 996, 997f
psoriasis vulgaris, 991, 991f–992f
vitiligo and leukoderma, 990, 990f
Geographical tongue, 975, 975f
Geographical breakdown of infectious disease incidence, 1018–1021
German measles, 770–771, 771f–772f
Giant cell arteritis, 390–391, 391f–392f
Giant congenital nevocellular nevus (GCNN), 276, 278, 280, 281f
Gilchrist's disease, 740–742, 741f
Gingival and buccal mucosa, disorders of, 976–979, 977f–978f
Glomus tumor, 186f
Glossitis migrans, 975, 975f
Glucagonoma syndrome, 490, 491f
Gnathophyma, 8
Gold-induced drug reactions, 554, 568
Gonococcal arthritis-dermatitis syndrome, 887, 888f
Gonococemia, 887, 888f
Gonorrhea, 885–886, 886f
Gougerot-Blum disease, 131, 133
Graft-versus-host disease (GVHD), 353–357
 acute, 353–354, 353t, 354f–355f
 chronic, 355–356, 356f–357f
Graham Little syndrome, 114
Gram-negative bacterial infections, 642–653
 Bartonella infections, 642–648
 folliculitis, 594
 Pseudomonas aeruginosa infections, 652–653
 tularemia, 649–650
Gram-positive bacterial infections associated with toxin production, 620–629
 scarlet fever, 626–628, 627f, 629f
 staphylococcal scalded-skin syndrome (SSSS), 620–622, 621f, 623f
 toxic shock syndrome, 624–626, 625f
Granuloma annulare (GA), 120–122, 121f
 variants, 120
Granuloma inguinale, 905–906, 906f
Granuloma telangiectaticum, 184
Granuloma venereum, 905–906, 906f
Graves' disease, 421, 421f
Great imitator. *See* Syphilis
Grover's disease (GD), 112, 113f
Guttate parapsoriasis, 134, 135f
 of Juliusberg (pityriasis lichenoides chronica), 134

GVHD. *See* Graft-versus-host disease

H

Hailey-Hailey's disease, 92, 93f
Hair
 dermatophytoses, 700–707
 follicle disorders and related disorders, 926–951
 growth disorders. *See* Alopecia
 hirsutism, 946–948, 947f, 949f
 hypertrichosis, 950, 951f
 drug-induced, 950, 951f
 hypertrichosis lanuginosa, 950
 fungal infections. *See* Skin and hair, fungal infections of
Hairy tongue, 974, 974f
Hallopeau, acrodermatitis continua of, 69
Halo nevomelanocytic nevus, 164, 165f
Hand-foot-and-mouth disease (HFMD), 776–778, 777f
Hand-Schüller-Christian disease, 508–512, 509f, 509t–510t, 511f, 513f
Hands, toxic contact dermatitis of, 20, 21f
Hansen's disease. *See* Leprosy
Harlequin fetus, 80
Heerford syndrome, 403
Helminths, 845t
Hemangiomas of infancy, 173–174, 174f–175f
Hematologic diseases, skin signs of, 496–521
 cryoglobulinemia, 504–506, 505f, 507f
 disseminated intravascular coagulation (DIC), 500–502, 501f, 503f
 Langerhans cell histiocytosis (LCH), 508–512, 509f, 509t–510t, 511f, 513f
 leukemia cutis (LC), 518–520, 519f, 521f
 mastocytosis, 514–516, 514t, 515f, 516t, 517f
 thrombocytopenic purpura, 496–498, 497f, 499f
Hemiptera, 822
Heparin-induced necrosis, 549, 551f
Hereditary epidermolysis bullosa. *See* Epidermolysis bullosa
Hereditary (hair) thinning, 932–936, 933f, 935f–936f
Herpes febrilis. *See* Herpes simplex virus
Herpes gestationis, 409–410, 410f
Herpes gladiatorum. *See* Herpes simplex virus
Herpes labialis. *See* Herpes simplex virus
Herpes simplex virus (HSV), 781–785, 785f
 epidemiology, 781, 783
 genital infections. *See* Genital herpes infections associated with systemic immunocompromise, 794–798, 795f, 797f, 799f, 925
 management, 784–785

- neonatal, 789–790, 790f–791f
nongenital infection, 786–787, 787f
widespread cutaneous infection associated with cutaneous immunocompromise, 791–793, 792f–793f
- Herpes zoster (HZ), 805–808, 807f, 809f
Herpetic folliculitis, 595–596, 599f
Herpetic whitlow. *See* Herpes simplex virus
HFMD (hand-foot-and-mouth disease), 776–778, 777f
- HHV. *See* Human herpesviruses
- Hidradenitis axillaris, 14–16, 15f
Hidradenitis suppurativa, 14–16, 15f, 17f
management, 16
- Hirsutism, 946–948, 947f, 949f
Histamine-releasing drugs, reaction to, 556
- Histiocytosis, type II, 508–512, 509f, 509t–510t, 511f, 513f
- Histoplasmosis, 737–738, 739f
- HIV disease, 910–925
acute HIV syndrome, 912–915, 915f, 915t
eosinophilic folliculitis (EF), 916–918, 917f
Kaposi's sarcoma, 525–526, 528, 530f–531f
lipodystrophy syndrome, 921–923, 922f–923f
oral hairy leukoplakia (OHL), 919–920, 920f
overview, 911t
tuberculosis, 661
variations of common mucocutaneous disorders in HIV disease, 924–925
aphthous stomatitis, 924
dermatophytoses, 924
drug eruptions, 924
herpes simplex virus infection, 794, 925
human papilloma virus (HPV), 925
invasive fungal infection with cutaneous dissemination, 925
molluscum contagiosum, 925
mucosal candidiasis, 924
nonmelanoma skin cancers, 924
syphilis, 900, 925
varicella zoster virus infection, 925
- Hot tub folliculitis, 594, 595f
- Houseflies, 822, 825f
- Human herpesviruses (HHV), 781–799
herpes simplex virus (HSV). *See* Herpes simplex virus
human herpesvirus-6 and -7 infections (exanthema subitum), 818, 819f
immunocompromised individuals, 782t
overview, 781, 782t
varicella-zoster virus (VSV) infections. *See* Varicella-zoster virus infections
- Human orf, 758, 759f
- Human papillomavirus (HPV) infections, 760–765
epidemiology, 760–761
epidermodysplasia verruciformis, 762
management, 764
sexually transmitted, 862–873, 863f–867f
management, 866–868
squamous cell carcinoma of anogenital skin, 869–872, 870f–873f
types and associated lesions, 761t
variation in HIV disease, 925
verruca plana (flat warts), 761–762, 765f
verruca plantaris (plantar warts), 761–762, 765f
verruca vulgaris (common warts), 761–762, 762f–763f
- Hydantoin derivatives drug reaction, 554
- Hydroxychloroquine-induced pigmentation, 567
- Hymenoptera, 821, 823
- Hypercorticism, 420, 420f
- Hyperkeratosis, epidermolytic, 78, 79f
- Hyperpigmentation following inflammatory disorders, 330, 330f
- Hyperplasias. *See* Benign neoplasms and hyperplasias
- Hypersensitivity syndrome, drug-induced, 564–565, 565f
- Hypersensitivity vasculitis, 381–384, 382f–383f
- Hyperthyroidism, 421, 421f
- Hypertrichosis, 950, 951f
- Hypertrophic scars, 206–207, 207f
- Hypomelanosis, postinflammatory, 332f
- Hypopigmentation following inflammatory disorders, 331, 331f–333f
- Hypothyroidism, 422, 423f
- HZ (herpes zoster), 805–808, 807f, 809f

I

- ICD (irritant contact dermatitis), 18–20, 19f, 22, 22t, 24–25
- Ichthyoses, 70–81
epidermolytic hyperkeratosis, 78, 79f
ichthyosis vulgaris, 70–72, 71f–73f
distribution, 72f
lamellar ichthyosis, 76–77, 77f
newborn (collodion baby), 80, 81f
X-linked ichthyosis (XLI), 74–75, 75f
- Ichthyosiform dermatoses, 70–83
- IgE dermatitis, 30–35, 31f–33f, 35f
- ILVEN (inflammatory linear verrucous epidermal nevus), 202f
- Immune, autoimmune, and rheumatic diseases, skin signs of, 334–405
- Immunotherapeutics, drug reaction to, 556

- Impetigo, 586–590, 587f–589f
- Infections
- bacterial. *See* Bacterial infections involving the skin
 - fungal
 - HIV disease, 925
 - skin and hair. *See* Skin and hair, fungal infections of
 - by geographic area, 1018–1021
 - viral. *See* Viral infections of skin and mucosa
- Infectious folliculitis, 592–599
- Candida albicans*, 594
 - classification, 593
 - demodicidosis, 595
 - dermatophytic, 594, 597f
 - gram-negative, 594
 - herpetic, 595–596, 599f
 - hot tub, 594, 595f
 - management, 596, 598t
 - molluscum syncosis, 595
 - Pityrosporum*, 594, 599f
 - S. aureus*, 592, 593f–594f, 594
 - syphilitic, 595
 - tinea capitis, 594
- Infective endocarditis, 630–634, 635f
- cutaneous manifestations, 633t
 - epidemiology, 630
 - Janeway lesions, 631f, 632
 - Osler's nodes, 632, 633f
- Infestations. *See* Insect bites and infestations
- Inflammatory disorders, 106–151
- hyperpigmentation following, 330, 330f
 - hypopigmentation following, 331, 331f–333f
 - inflammatory linear verrucous epidermal nevus (ILVEN), 202f
 - metastatic carcinoma, 479
- Infundibular cyst, 188f
- Injecting drug use, cutaneous signs of, 570, 571f
- Insect bites and infestations, 820–857
- arthropod bites, cutaneous reactions to, 820–825, 822f–825f
 - cutaneous larva migrans (CLM), 844–846, 845f, 845t, 847f
 - leishmaniasis. *See* Leishmaniasis
 - pediculosis, 826–833
 - pediculosis capitis, 827–830, 829f
 - pediculosis corporis, 833, 833f
 - pediculosis pubis (phthiriasis), 830–832, 831f–832f
 - scabies. *See* Scabies
 - water-associated, 848–850, 848t, 849f–850f
- Interferon- α -induced necrosis, 549, 551f
- Intertrigo, 584, 584f–585f; 710, 710f–713f
- Invasive fungal infections, 726–745
- chromomycosis, 729–730, 730f
 - disseminated coccidioidomycosis, 743–744, 745f
 - disseminated cryptococcosis, 734–736, 735f
 - histoplasmosis, 737–738, 739f
 - in HIV disease, 925
 - mycetoma, 726–728, 727f, 728t
 - North American blastomycosis, 740–742, 741f
 - sporotrichosis, 731–732, 733f
- Invasive squamous cell carcinoma (SCC), 257–260, 984, 984f
- Iron-induced pigmentation, 568
- Irritant contact dermatitis (ICD), 18–20, 19f, 22, 22t, 24–25
- Irritation fibroma, 979
- Isoniazid drug reaction, 554
- Isthmus catagen cyst, 189f
- J**
- Janeway lesions, 631f, 632
- Jock itch, 694, 695f
- K**
- Kala-azar. *See* Leishmaniasis
- Kaposi's sarcoma (KS), 525–529, 527f, 529f–531f
- African-endemic, 525, 528
 - classic, 525, 527f, 528
 - HIV-associated, 525–526, 528, 530f–531f
 - iatrogenic immunosuppression-associated, 525–526, 528
 - management, 528–529
- Kasabach-Merritt syndrome, 174
- Kawasaki's disease (KD), 397–399, 398f–399f
- Keloids, 206–207, 208f
- Keratoacanthoma, 196, 197f
- Keratosis pilaris, 71, 73f
- Klippel-Trénaunay-Weber syndrome, 176, 179
- Koebner phenomenon, 314, 317f
- Koenen's tumors, 437
- Kraurosis (lichen sclerosus), 128–130, 129f
- KS. *See* Kaposi's sarcoma
- L**
- Lamellar ichthyosis, 76–77, 77f
- Langerhans cell histiocytosis (LCH), 508–512, 509f, 509t–510t, 511f, 513f
- Late-onset prurigo of pregnancy, 406–408, 407f–408f
- LC (leukemia cutis), 518–520, 519f, 521f
- LE. *See* Lupus erythematosus
- Leg ulcers, 468–473, 469f, 471f, 473f
- arterial, 468, 471f, 472–473

- hypertension, associated with, 470, 471*f*
 neuropathic and diabetic, 468, 470,
 472–473
 venous, 468–469, 469*f*, 472–473
- Leiner's disease, 47
- Leishmaniasis, 851–856, 853*f*, 855*f*, 857*f*
 classification, 851
 management, 856
 mucous membrane, 854
 New World, 854, 857*f*
 Old World, 852, 853*f*, 854, 855*f*
- Leishmaniasis recidivans, 854
- Lentiginoses, genital, 988, 989*f*
- Lentigo maligna (LM), 291–292
- Lentigo maligna melanoma (LMM), 291–292,
 292*f*, 308*f*
- Leonine facies, 535, 541*f*
- Lepidoptera, 823
- Leprosy, 654–660, 657*f*, 658*t*, 659*f*–660*f*
 borderline, 654–656, 658, 660*f*
 epidemiology, 654
 lepromatous, 654–656, 658–659, 659*f*
 pathogenesis, 655–656
 tuberculoid, 654–655, 657*f*, 658
- Letterer-Siwe syndrome, 508–512, 509*f*,
 509*t*–510*t*, 511*f*, 513*f*
- Leukemia cutis (LC), 518–520, 519*f*, 521*f*
- Leukoderma, anogenital, 990
- Leukoplakia, 983
- LGV (lymphogranuloma venereum), 907–909,
 909*f*
- Lice. *See* Pediculosis
- Lichen aureus, 131, 133
- Lichen planus (LP), 114–118, 115*f*, 116*t*,
 117*f*, 119*f*, 981, 981*f*
 actinic, 114
 anogenital, 993, 993*f*–994*f*
 disorders with similar eruptions, 116, 116*t*
 drug-induced, 116*t*
 follicular, 114
 hypertrophic, 114, 116, 117*f*
 mucous membrane, 114, 116
 nails, 954, 957*f*
 reticular, 114, 119*f*
 ulcerative, 114
 vesicular, 114
- Lichen purpuricus. *See* Lichen aureus
- Lichen sclerosus (LS), 128–130, 129*f*
 anogenital, 998, 999*f*
 genital, 128
 nongenital, 128
- Lichen sclerosus et atrophicus. *See* Lichen
 sclerosus
- Lichen simplex chronicus (LSC), 36–38,
 37*f*–38*f*, 996, 996*f*
 distribution, 36, 37*f*
- Lichenoid drug eruptions, 547
- Lighting techniques, 1015
- Lime dermatitis, 221, 222*f*
- Linear IgA dermatosis, 105, 105*f*
- Lipodystrophy syndrome, HIV-associated,
 921–923, 922*f*–923*f*
- Lipoma, 203*f*
- Lipomatosis, 203*f*
- Livedo reticularis, 358–360
 Sneddon's syndrome, 358, 359*t*, 360
 symptomatic (livedo racemosa), 358–360,
 359*f*, 359*t*
- LM (lentigo maligna), 291–292
- LMM (lentigo maligna melanoma), 291–292,
 292*f*, 308*f*
- LP. *See* Lichen planus
- LS. *See* Lichen sclerosus
- LSC. *See* Lichen simplex chronicus
- Lucio's reaction, 656, 660
- Lues. *See* Syphilis
- Lupus erythematosus (LE), 361–372, 982, 982*f*
 diagnosis, 364, 366*t*
 Gilliam's classification, 362*t*
 systemic lupus erythematosus (SLE),
 361–367
 acute (ACSL), 361–362, 362*t*, 363*f*,
 364, 366*t*, 367, 367*f*
 chronic (CCLE), 361, 362*t*, 365*f*,
 369–371, 371*f*–372*f*
 subacute (SCLE), 361, 362*t*, 364*f*,
 368–369
- Lupus erythematosus-like syndrome (drug re-
 action), 548
- Lupus erythematosus profundus, 370–371,
 372*f*
- Lupus panniculitis, chronic, 370–371, 372*f*
- Lupus pernio, 403, 405*f*
- Lyell's syndrome. *See* Toxic epidermal necrol-
 ysis
- Lyme borreliosis, 124, 672–683, 675*f*–679*f*,
 681*f*
 acrodermatitis chronica atrophicans, 674,
 676, 678*f*–679*f*, 680, 681*f*
 borrelial lymphocytoma, 673, 677*f*
 deer tick feeding, 675*f*
 epidemiology, 672
 erythema migrans, 673–674, 675*f*–676*f*,
 676, 680
 management, 680–681
 secondary lesions, 673–674, 677*f*
 staging, 673
- Lymphadenitis, nonbacterial regional (cat-
 scratch disease), 643–644, 645*f*
- Lymphangitis, 604, 618, 619*f*
- Lymphatic malformation (lymphangioma), 187*f*
- Lymphogranuloma inguinale, 907–909, 909*f*

- Lymphogranuloma venereum (LGV), 907–909, 909f
- Lymphomas and sarcoma, 522–545
- adult T cell leukemia/lymphoma (ATLL), 532–533, 533f–534f
- cutaneous B cell lymphoma, 543, 543f–544f
- cutaneous T cell lymphoma (CTCL), 535–537, 537f–541f
- classification, 536t–537t
- management, 536–537
- Sézary’s syndrome, 535, 537, 542
- dermatofibrosarcoma protuberans, 545, 545f
- Kaposi’s sarcoma. *See* Kaposi’s sarcoma
- lymphomatoid papulosis, 522–524, 523f
- Lymphomatoid papulosis, 522–524, 523f
- Lymphoreticulosis, benign (cat-scratch disease), 643–644, 645f
- M**
- Macroglossia, 336, 337f
- Macule, 1008f
- Maculopapular drug reaction (exanthematous drug reactions), 547, 552–555, 553f
- Madura foot, 726–728, 727f, 728t
- Maduromycetoma, 726–728, 727f, 728t
- Magnification techniques, 1015
- Majocchi’s disease, 131, 133f
- Male-pattern baldness, 932–936, 933f, 935f–936f
- Malignant appendage tumors, 268
- Mammary Paget’s disease (MPD), 484, 485f
- Marfucci’s syndrome, 179
- Mark (capillary hemangioma of infancy), 173–174, 174f–175f
- Martorell’s ulcer, 470, 471f
- Mastocytosis, 514–516, 514t, 515f, 516t, 517f
- Measles, 770–771, 771f–772f, 773–774, 775f
- MED (minimum erythema dose), 211
- Melanocytes, disorders of, 160–172
- acquired melanocytic nevocellular nevi, 160–161
- blue nevus, 166, 167f
- compound melanocytic nevocellular nevi, 161, 163f
- dermal melanocytic nevocellular nevi, 162, 163f
- halo nevomelanocytic nevus, 164, 165f
- junctional melanocytic nevocellular nevi, 161, 162f
- Mongolian spot, 171f
- nevus of Ota, 172f
- nevus spilus, 170f
- spitz nevus, 168–169, 169f
- Melanoma, 270–311
- acral lentiginous melanoma (ALM), 295–296, 297f
- anogenital, 1006, 1006f–1007f
- classification, 272
- desmoplastic, 293–294, 294f
- epidemiology, 270
- follow-up, 307t
- in situ, 277f, 282–284, 283f
- screening technique for melanoma risk, 282
- lentigo maligna (LM), 283f, 291–292
- lentigo maligna melanoma (LMM), 291–292, 292f, 307f
- localization, 311f
- management, 302
- metastatic, 299, 300f–301f
- mucosa, malignant, 298
- nails, 956, 957f
- nodular melanoma (NM), 289–290, 290f, 310f
- oral, 985, 985f
- overview, 270–272, 271t
- precursors, 270–281
- Clark melanocytic nevus (CMN), 272–276, 274t, 275f, 277f
- classification, 272
- congenital nevomelanocytic nevus (CNN), 278–280, 279f, 281f
- recurrent, 483f
- signs of, 302
- staging and work-up, 306t–307t
- superficial spreading melanoma (SSM), 277f, 283f, 284–286, 285f, 287f–288f, 309f
- Melasma, 327–328, 329f
- Meleney’s gangrene, 616
- Meningococemia, 637–638, 639f, 640, 641f
- Merkel cell carcinoma, 269
- Metabolic diseases. *See* Genetic, metabolic, endocrine, and nutritional diseases
- Metastatic cancer to the skin, 479–483, 480f–481f, 483f
- patterns of cutaneous involvement, 479–480, 482
- Mibelli, angiokeratoma of, 183f
- Microscopic examinations, 1016
- Midges, 822
- Migratory glossitis, 975, 975f
- Migratory necrolytic erythema, 490, 491f
- Migratory phlebitis, 460
- Mikulicz, recurrent aphthae of, 976
- Milium, 190f
- Milker’s nodules, 758, 759f
- Minimum erythema dose (MED), 211
- Minocycline-induced pigmentation, 566, 569f
- Mites, 820–821
- Mohs surgery, 262, 262f
- Molluscum contagiosum, 754–757, 756f–757f
- in HIV disease, 925

- Molluscum syncosis, 595
Mondor's disease, 460
Mongolian spot, 171f
Moniliasis. *See* Candidiasis
Morbilli, 773–774, 775f
Morbilliform drug reaction (exanthematous drug reactions), 547, 552–555, 553f
Morphea, 123–124, 125f–127f, 128, 130
 circumscribed, 123, 125f
 frontoparietal, 123
 generalized, 123, 126f
 linear, 123, 127f
 pansclerotic, 123
Moths, 821
MPD (mammary Paget's disease), 484, 485f
Mucha-Habermann disease, 134, 135f
Mucocoele, 978, 978f
Mucocutaneous lymph node syndrome (Kawasaki's disease), 397–399, 398f–399f
Mucosa
 buccal and gingival, 976–979, 977f–978f
 malignant melanoma of, 298
 mucosal candidiasis in HIV disease, 924
 viral infections of. *See* Viral infections of skin and mucosa
Mucous cyst, 191f
Multiple idiopathic hemorrhagic sarcoma. *See* Kaposi's sarcoma
Munchausen's syndrome, 578, 578f
Mycetoma, 726–728, 727f, 728t
Mycobacterial infections, 654–671
 cutaneous nontuberculous infections, 666–671
 M. fortuitum complex, 670–671, 671f
 M. marinum, 666–668, 667f
 M. ulcerans, 668–669, 669f
 cutaneous tuberculosis infections, 661–666, 663f–665f
 epidemiology, 654
 leprosy. *See* Leprosy
Mycosis fungoides. *See* Cutaneous T cell lymphoma
Mycotic stomatitis, 714–716, 715f, 717f
Myleran-induced pigmentation, 568
Myrmecia, 760–762, 761t, 762f–763f, 765f
Myxedema, 422, 423f
Myxoid pseudocyst, 191f
- N**
Nail disorders, 952–973
 as clues to multisystem diseases, 968–969, 969f–973f
 cutaneous, 954–956, 955f–957f
 infections, 958, 959f–960f
 onychomycosis, 961–967, 963f, 965f
 normal nail apparatus, 953f
Necrobiosis lipoidica, 415–416, 416f
Necrotizing fasciitis, 614, 616
Necrotizing soft tissue infection, 604
Necrotizing vasculitis, 381–384, 382f–383f
Neisseria gonorrhoeae infections, 882–887, 883f, 886f, 888f
 disseminated, 887, 888f
 localized (gonorrhoea), 885–886, 886f
 management, 883–885
Neoplasms, benign. *See* Benign neoplasms and hyperplasias
Neurofibromatosis (NF), 440–442, 441f, 443f
 central or acoustic (NF2), 440, 442
 von Recklinghausen's (NF1), 440, 441f, 442, 443f
Neuropathy, diabetic, 413, 413f
Neurotic excoriations, 573f–575f
Nevus(i)
 araneus, 182f
 Becker's, 198f
 blue, 166, 167f
 blue rubber bleb, 179
 capillary hemangioma of infancy, 173–174, 174f–175f
 Clark melanocytic, 272–276, 274t, 275f, 277f
 dysplastic melanocytic, 272–276, 274t, 275f, 277f
 epidermal, 202f
 epithelioid spindle-cell, 168–169, 169f
 flammeus, 173, 176, 177f–178f
 giant congenital nevocellular, 276, 278, 280, 281f
 halo nevomelanocytic, 164, 165f
 nevocellular
 acquired, 160–161
 compound, 161, 163f
 dermal, 162, 163f
 junctional, 161, 162f
 nevomelanocytic, 164, 165f
 organoid, 201f
 of Ota, 172f
 pigmented spindle-cell, 168–169, 169f
 sebaceous, 201f
 small congenital nevus cell nevi, 280
 spilus, 170f
 spitz, 168–169, 169f
 strawberry, 173
NF. *See* Neurofibromatosis
Nikolsky phenomenon, 94, 1016
Nitrofurantoin drug reaction, 554
Nodular melanoma (NM), 289–290, 290f, 310f
Nodular metastatic carcinoma, 481f, 482

Nodular vasculitis, 395, 396*f*
Nodule, 1010*f*
Nonbiting flies, 821
Nonclostridial anaerobic cellulitis, 616
Nonsteroidal anti-inflammatory drugs (NSAIDs), reactions to, 552, 556
North American blastomycosis, 740–742, 741*f*
NSAIDs (nonsteroidal anti-inflammatory drugs), reactions to, 552, 556
Nummular eczema, 42, 43*f*
Nutritional diseases. *See* Genetic, metabolic, endocrine, and nutritional diseases

O

Oculocutaneous albinism, 322, 323*t*, 324, 325*f*
Ohio Valley disease, 737–738, 739*f*
Onychogryphosis, 954, 955*f*
Onycholysis, 954, 955*f*
Onychomycosis, 961–967, 963*f*, 965*f*
Oral hairy leukoplakia (OHL), 919–920, 920*f*
Orf, human, 758, 759*f*
Organoid nevus, 201*f*
Oriental sore. *See* Leishmaniasis
Oropharynx disorders, 974–987
 buccal and gingival mucosa, 976–979
 aphthous ulcer, 976–977, 977*f*
 mucocoele, 978, 978*f*
 oral fibroma, 979, 979*f*
 bullous diseases with oral manifestations, 980–982, 980*f*–982*f*
 lichen planus, 981, 981*f*
 lupus erythematosus, 982, 982*f*
 pemphigoid, 980
 pemphigus vulgaris, 980, 980*f*
 precancerous and cancerous lesions, 983–986, 983*f*–987*f*
 condyloma acuminatum, 986, 986*f*–987*f*
 invasive squamous cell carcinoma, 984, 984*f*
 leukoplakia, 983
 oral melanoma, 985, 985*f*
 squamous cell carcinoma in situ (erythroplasia), 983, 983*f*
 tongue, 974–975, 974*f*–975*f*
 fissured tongue, 975, 975*f*
 hairy tongue, 974, 974*f*
 migratory glossitis, 975, 975*f*
Osler-Weber-Rendu syndrome, 419, 419*f*
Osler's nodes, 632, 633*f*
Ota, nevus of, 172*f*
Otophyma, 8

P

Paget's disease, 482, 484–487, 485*f*, 487*f*
 extramammary, 486–487, 487*f*

 mammary, 484, 485*f*
Palmoplantar pustulosis, 66, 67*f*
Panarteritis nodosa, 384–386, 385*f*
Panniculitis, 146, 147*f*, 147*t*
 α_1 antitrypsin-deficiency, 146
 idiopathic lobular (Pfeiffer-Weber-Christian disease), 146
 lobular, 146, 147*t*
 pancreatic, 146, 147*f*
 septal, 146, 147*t*
Papule, 1009*f*
Paraneoplastic pemphigus (PNP), 96, 495, 495*f*
Parapsoriasis en plaques, 109–110, 110*f*–111*f*
 cutaneous T cell lymphoma (CTCL), progression to, 109–110
 large plaque, 109, 111*f*
 small plaque (digitate dermatosis), 109, 110*f*
Parasitosis, delusions of, 576, 576*f*–577*f*
Paronychia, 958, 959*f*
Pastia's lines, 626, 627*f*
Patch testing, 1016
Pediculosis, 826–833
Pediculosis captis, 827–830, 829*f*
Pediculosis corporis, 833, 833*f*
Pediculosis pubis (phthiriasis), 830–832, 831*f*–832*f*
Pellagra, 433, 433*f*
Pemphigoid, 980
 bullous, 98–100, 99*f*–100*f*
 cicatricial, 101, 101*f*
Pemphigus
 familial benign, 92, 93*f*
 paraneoplastic (PNP), 96, 495, 495*f*
Pemphigus erythematosus (PE), 96
Pemphigus foliaceus, 96
Pemphigus vegetans, 96
Pemphigus vulgaris, 94–97, 95*f*, 97*f*, 980, 980*f*
Penicillin-induced urticaria, 559*f*
Penile intraepithelial neoplasm, 869
Penile lentigo, 988, 989*f*
Periadenitis mucosa necrotica recurrens, 976
Periarteritis nodosa, 384–386, 385*f*
Perifolliculitis, dissecting, 941, 944*f*
Perineum. *See* Genitalia, perineum, and anus, disorders of
Periocular xanthoma, 445, 446*f*
Perioral dermatitis, 12, 13*f*
Periorbital dermatitis, 13*f*
Peutz-Jeghers syndrome (PJS), 492, 492*f*
Pfeiffer-Weber-Christian disease, 146
Phenolphthalein-induced drug reactions, 561*f*
Phenothiazine-induced drug reaction, 554, 568
Phenytoin-induced drug reactions, 565*f*, 567

- Photoaging. *See* Dermatoheliosis
- Photopatch testing, 1016
- Photosensitivity and photoinduced disorders, 210–247
 - classification and overview, 210
 - diagnosis, 234, 235*t*, 236, 237*t*
 - drug-induced photosensitivity, 223–229, 547
 - photoallergic drug-induced, 227–228, 228*f*–229*f*
 - phototoxic drug-induced, 223–225, 224*f*–225*f*, 226*t*
 - management, 236
- Phototypes, skin, 212*t*
- Phthisis, 661
- Phytophotodermatitis, 221, 222*f*
- Pigmentary disorders, 312–333
 - albinism. *See* Albinism
 - drug reactions, 549, 566–568, 567*f*, 569*f*
 - specific drugs, 566–568
 - following inflammation of the skin, 330–331, 330*f*–333*f*
 - melasma, 327–328, 329*f*
 - vitiligo. *See* Vitiligo
- Pigmented lesions, management (to facilitate early diagnosis of melanoma), 302
- Pigmented purpuric dermatoses, 131–133, 132*f*–133*f*
 - Gougerot-Blum disease, 131, 133
 - lichen aureus, 131, 133
 - Majocchi's disease, 131, 133*f*
 - Schamberg's disease, 131, 132*f*
- Pigmented spindle-cell nevus, 168–169, 169*f*
- Pilar cyst, 189*f*
- Pinch purpura, 335*f*
- Pitted keratolysis, 582–583, 583*f*
- Pityriasis alba, 331, 333*f*
- Pityriasis lichenoides, 134, 135*f*
- Pityriasis lichenoides chronica, 134, 135*f*
- Pityriasis lichenoides et varioliformis acuta (Mucha-Habermann disease), 134, 135*f*
- Pityriasis rosea, 106–108, 107*f*
 - distribution, 107*f*
 - drug reactions, 548
 - herald patch, 107*f*
- Pityriasis sicca (dandruff), 45–48, 47*f*
- Pityriasis versicolor, 331, 331*f*, 722–724, 723*f*, 725*f*
- Pityrosporum* folliculitis, 594, 599*f*
- PJS (Peutz-Jeghers syndrome), 492, 492*f*
- Plantar warts, 761–762, 765*f*
- Plaque, 1009*f*
- Plumber's itch. *See* Cutaneous larva migrans
- PNP (paraneoplastic pemphigus), 96, 495, 495*f*
- Poison ivy dermatitis, 26–28, 28*f*–29*f*
- Poison oak dermatitis, 26–28
- Polyarteritis nodosa, 384–386, 385*f*
- Polymorphic eruption of pregnancy, 406–408, 407*f*–408*f*
- Polymorphous light eruption, 230–232, 231*f*, 233*f*
- Porphyrias, 238–247
 - erythropoietic, 245–247, 246*f*–247*f*
 - porphyria cutanea tarda, 238–240, 238*t*, 240*f*–241*f*, 241*t*
 - drug reaction, 547
 - variegata, 242–244, 243*f*, 244*t*
- Port-wine stain, 176, 177*f*–178*f*
- Postinflammatory hyperpigmentation, 330, 330*f*
- Postinflammatory hypomelanosis, 331, 331*f*–332*f*
- Poxvirus infections, 754–759
 - human orf, 758, 759*f*
 - Milker's nodules, 758, 759*f*
 - molluscum contagiosum, 754–757, 756*f*–757*f*
- Precancerous lesions and cutaneous carcinomas, 248–269
 - epidermal, 248–254
 - invasive squamous cell carcinoma, 257–260
 - malignant appendage tumors, 268
 - radiation dermatitis, 252–254
- Pregnancy, diseases in, 406–410
 - herpes gestationis, 409–410, 410*f*
 - pruritic urticarial papules and plaques, 406–408, 407*f*–408*f*
- Pressure sore, 474–477, 475*f*–476*f*
- Pressure ulcers, 474–477, 475*f*–476*f*
 - stages, 474
- Pregnancy, diseases in, 406–410
- Progressive bacterial synergistic gangrene, 616
- Progressive systemic sclerosis. *See* Scleroderma
- Prosthetic valve endocarditis, 631
- Pruritic urticarial papules and plaques, 406–408, 407*f*–408*f*
- Pruritus, generalized, without diagnostic skin lesions, 425, 425*t*–427*t*, 427*f*
- Pruritus ani, 427, 427*f*, 996, 997*f*
- Pseudofolliculitis barbae, 941, 945*f*
- Pseudolymphoma drug reaction, 548
- Pseudomonas aeruginosa* infections, 652–653
- Pseudopelade of Brocq, 941, 942*f*–943*f*
- Pseudoxanthoma elasticum (PXE), 434–436, 435*f*–436*f*
- Psoriasis, 50–69, 52*f*–55*f*, 57*f*, 58*t*, 59*f*, 61*f*, 62*t*, 63*f*–65*f*
 - anogenital, 991, 991*f*–992*f*
 - arthritis, 51–52, 64*f*
 - body folds, 65
 - distribution, 52*f*, 55*f*

drug reaction, 548
erythroderma, 51
generalized acute pustular psoriasis (von Zumbusch), 68–69, 69f
nails, 64, 64f, 954, 956f
palmoplantar pustulosis, 66, 67f
palms and soles, 63, 63f–64f
perianal and genital regions, 65, 65f
scalp, 56, 57f
widespread, 58, 58t, 59f, 60–62, 61f, 62t
 management, 58–62, 58t, 62t
Psychiatric etiology, disorders of, 572–579
 delusions of parasitosis, 576, 576f–577f
 dysmorphic syndrome, 579
 Munchausen's syndrome, 578, 578f
 neurotic excoriations, 573f–575f
Pubic lice, 830–832, 831f–832f
Purpura drug reaction, 547–548
Purpura fulminans, 500, 501f, 503f
Pustular drug eruptions, 548
Pustular psoriasis, acute (von Zumbusch), 68–69, 69f
Pustule, 1011f
Pustulosis, palmoplantar, 66, 67f
PXE (pseudoxanthoma elasticum), 434–436, 435f–436f
Pyodermas, 586–603
 abscess, furuncle, and carbuncle, 600–602, 601f, 603f
 impetigo and ecthyma, 586–590, 587f–589f, 591f
 infectious folliculitis. *See* Infectious folliculitis
 pathogenesis, 586
 pyoderma gangrenosum, 148, 149f
Pyogenic granuloma, 184, 185f

Q
Queyrat, erythroplasia of, 260f
Quinacrine-induced pigmentation, 567

R
Rabbit fever, 649–650, 651f
Radiation dermatitis, 252–254, 253f–254f
 squamous cell carcinoma in situ, 255–256, 256f
Ranula, 978, 978f
Rashes in acutely ill febrile patients, 158–159, 159t
 diagnosis, 158–159, 159t
Raynaud's disease/phenomenon, 373, 375f, 377–380, 377f, 379f–380f
 acrogangrene, 378, 380f
 causes, 379t
Reiter's syndrome (RS), 400–402, 401f

Rheumatic diseases, skin signs of. *See* Immune, autoimmune, and rheumatic diseases, skin signs of
Rhinophyma, 8, 10, 11f
Rickettsial infections, 746–753, 766
 Rocky Mountain spotted fever, 750–752, 752f–753f
 spotted fevers, 746–753
 etiology and geographic distribution, 747
 rickettsialpox, 748, 749f
 tâche noire, 749f
Rickettsialpox, 748, 749f
Ringworm, 688
 beard, 706, 706f–707f
 scalp, 700–704, 701f–702f, 705f
Rocky Mountain spotted fever, 750–752, 752f–753f
Rosacea, 8–10, 9f, 11f
 blepharophyma, 8
 gnathophyma, 8
 otophyma, 8
 rhinophyma, 8, 10, 11f
Rosacea-like dermatitis, 12, 13f
Roseola infantum, 818, 819f
RS (Reiter's syndrome), 400–402, 401f
Rubella, 770–771, 771f–772f
Rubeola, 773–774, 775f

S

Sailor's skin, 214
Salmon patch, 176
Sand fleas, 821
Sandworm eruption. *See* Cutaneous larva migrans
San Joaquin Valley fever, 743–744, 745f
Sarcoidosis, 403–404, 404f–405f
Sarcoma. *See* Lymphomas and sarcoma
Scabies, 834–842, 837f, 839f, 841f, 843f
 crusted or Norwegian scabies, 838, 840, 841f, 842
 distribution, 837f, 838
 elderly, 838
 epidemiology, 834
 infants and young children, 838, 839f
 laboratory diagnosis, 1016–1017
 nodular scabies, 838, 839f, 840, 842
Scaling (desquamation), 1013f
Scarlet fever, 626–628, 627f, 629f
Scars, hypertrophic, 206–207, 207f
SCC. *See* Squamous cell carcinoma
Schamberg's disease, 131, 132f
Schistosome dermatitis, 848t, 849, 849f
Schönlein-Henoch purpura, 384
Scleroderma, 373–377, 375f–377f
 circumscribed, 123–124, 125f–127f
 Crest syndrome, 374, 377, 377f


- drug reaction, 548
 - localized, 123–124, 125*f*–127*f*
 - scleroderma-like conditions, 377
- Sclerosing hemangioma, 204, 205*f*
- SCNN (small congenital nevus cell nevi), 280
- Scorpions, 821
- Scrotal tongue, 975, 975*f*
- Scrum pox. *See* Herpes simplex virus
- Scurvy, 428–429, 429*f*
- Seabather's eruption, 848*t*, 850, 850*f*
- Sebaceous cyst, 188*f*
- Sebaceous glands, 2–13
- Sebaceous hyperplasia, 200*f*
- Sebopsoriasis, 47*f*
- Seborrheic dermatitis, 45–48, 46*f*–47*f*
 - distribution, 45–46
- Seborrheic keratosis, 192–193, 193*f*–195*f*
- Sedge pool itch, 848*t*, 849, 849*f*
- Senear-Usher syndrome, 96
- Senile (hem)angioma, 181*f*
- Senile sebaceous hyperplasia, 200*f*
- Sepsis and septic shock, 636–640, 639*f*, 641*f*
 - epidemiology, 636
 - management, 640
 - physical examination, 637–638
- Serum sickness, 547
- Sexually transmitted diseases (STDs), 858–909
 - chancroid, 901–904, 902*f*–903*f*
 - donovanosis, 905–906, 906*f*
 - genital herpes. *See* Genital herpes
 - human papillomavirus (HPV) mucosal infections, 862–873, 863*f*–867*f*
 - management, 866–868
 - squamous cell carcinoma of anogenital skin, 869–872, 870*f*–873*f*
 - lymphogranuloma venereum (LGV), 907–909, 909*f*
 - management, 858
 - Neisseria gonorrhoeae* infections, 882–887, 883*f*, 886*f*, 888*f*
 - disseminated, 887, 888*f*
 - localized (gonorrhea), 885–886, 886*f*
 - management, 883–885
 - overview, 858, 859*t*–861*t*
 - syphilis. *See* Syphilis
- Sézary's syndrome, 535, 537, 542
- Shingles (herpes zoster), 805–808, 807*f*, 809*f*
- Silver-induced pigmentation, 568
- Sister Mary Joseph nodule, 482
- Sjögren syndrome, 403
- Skin and hair, fungal infections
 - candidiasis. *See* Candidiasis
 - dermatophytoses. *See* Dermatophytoses
 - invasive infections. *See* Invasive fungal infections
 - pityriasis versicolor, 722–724, 723*f*, 725*f*
- Skin lesion, types, 1008–1014
 - bulla, 1011–1012
 - crusts, 1013*f*
 - desquamation (scaling), 1013*f*
 - macule, 1008*f*
 - nodule, 1010*f*
 - papule, 1009*f*
 - plaque, 1009*f*
 - pustule, 1011*f*
 - ulcer, 1014*f*
 - vesicle, 1011*f*–1012*f*
 - wheel, 1010*f*
- Skin phototypes, 212*t*
- Skin tag, 209*f*
- Small congenital nevus cell nevi (SCNN), 280
- Sneddon's syndrome, 359*t*, 360
- Soft chancre, 901–904
- Soft fibroma, 209*f*
- Soft tissue infections, bacterial. *See* Bacterial infections, soft tissue infections
- Solar keratosis, 217, 219, 220*f*
- Solar lentiginos, 219*f*
- Solar lentigo, 217, 218*f*
- Solitary histiocytoma, 204, 205*f*
- Spider angioma, 182*f*
- Spider nevus, 182*f*
- Spider telangiectasia, 182*f*
- Spiders, 821
- Spitz nevus, 168–169, 169*f*
- Sporotrichosis, 731–732, 733*f*
- Spotted fevers, 746–753
- Squamous cell carcinoma (SCC)
 - in situ, 255–256, 256*f*, 983, 983*f*
 - anogenital, 1000–1002, 1000*f*–1001*f*, 1003*f*
 - nails, 954, 957*f*
 - invasive, 257–260
- Staphylococcal scalded-skin syndrome (SSSS), 620–622, 621*f*, 623*f*
- Statis dermatitis, 462, 464, 465*f*, 469
- STDs. *See* Sexually transmitted diseases
- Stevens-Johnson syndrome, 140–143, 141*f*, 547
- Strawberry nevus, 173
- Sturge-Weber syndrome, 176
- Sulfonamides, drug reaction to, 554
- Sun damage, acute (sunburn), 211–213, 213*f*
 - skin phototypes, 211, 212*t*
- Superficial spreading melanoma, 277*f*, 283*f*, 284–286, 285*f*, 287*f*–288*f*, 309*f*
- Sutton's disease, 976
- Sutton's leukoderma acquisitum centrifugum, 164, 165*f*
- Sweet's syndrome, 150, 151*f*
- Swimmer's itch, 848*t*, 849, 849*f*
- Swimming pool granuloma, 666–668, 667*f*

- Symptomatic primary HIV infection, 912–915, 915*f*, 915*t*
- Synergistic necrotizing cellulitis, 616
- Synovial cyst, 191*f*
- Syphilis, 889–904
 - classification of clinical stages, 890
 - in HIV disease, 900
 - laboratory examinations, 889–891
 - latent, 899
 - management, 891–892
 - primary, 890, 892, 893*f*–894*f*
 - secondary, 890, 895, 896*f*–898*f*
 - tertiary, 890, 899, 900*f*
 - variation in HIV disease, 925
- Syphilitic folliculitis, 595
- Syringoma, 199*f*
- Systemic lupus erythematosus. *See* entry under Lupus erythematosus
- Systemic scleroderma. *See* Scleroderma
- Systemic sclerosis. *See* Scleroderma
- ## T
- Tabandae, 822
- Telangiectasia, hereditary hemorrhagic, 419, 419*f*
- Telangiectatic carcinoma, 479, 481*f*
- Telogen effluvium, 937–939, 938*t*–939*t*, 939*f*
- Temporal arteritis, 390–391, 391*f*–392*f*
- TEN (toxic epidermal necrolysis), 140–143, 141*f*, 547
- Tendinous xanthoma, 447, 447*f*
- Tetracycline-induced drug eruption, 563*f*
- Thrombocytopenic purpura, 496–498, 497*f*, 499*f*
- Thrombophlebitis, 458–460, 459*f*
- Thrush, 714–716, 715*f*, 717*f*
- Ticks, 821
- Tinea barbae, 706, 706*f*–707*f*
- Tinea capitis, 594, 700–704, 701*f*–702*f*, 705*f*
- Tinea corporis, 696–697, 696*f*–697*f*
- Tinea cruris, 694, 695*f*
- Tinea facialis, 698–699, 698*f*–699*f*, 707*f*
- Tinea incognito, 699, 699*f*
- Tinea manuum, 693–694, 693*f*
- Tinea pedis, 688–690, 689*f*, 691*f*–692*f*
- Tinea tonsurans, 700–704, 701*f*–702*f*, 705*f*
- Tinea versicolor. *See* Pityriasis versicolor
- Tongue disorders, 974–975, 974*f*–975*f*
- Torulosis, 734–736, 735*f*
- Toxic rash of pregnancy, 406–408, 407*f*–408*f*
- Toxic epidermal necrolysis (TEN), 140–143, 141*f*, 547
- Toxic oil syndrome, 377
- Toxic shock syndrome, 624–626, 625*f*
- Toxicodendron dermatitis, 26–28, 28*f*–29*f*
- Transient acantholytic dermatosis, 112, 113*f*
- Traumatic epidermoid cyst, 190*f*
- Traumatic fibroma, 979
- Trichilemmal cyst, 189*f*
- Trichoepithelioma, 199*f*
- Tricholemmomas, 488, 489*f*
- Tuberculosis, cutaneous, 661–666, 663*f*–665*f*
 - acute miliary (AMT), 661–662, 666
 - lupus vulgaris (LV), 661–662, 664, 664*f*, 666
 - metastatic abscess (MTA), 661–662, 664, 666
 - orificial (OT), 661–662, 664, 665*f*
 - primary inoculation tuberculosis, 661–662, 663*f*, 666
 - scrofuloderma, 661–662, 664, 665*f*, 666
- Tuberculosis verrucosa cutis, 661–662, 663*f*, 664, 666
- Tuberous sclerosis, 437–438, 438*f*–439*f*
- Tuberous xanthoma, 448, 448*f*
- Tularemia, 649–650, 651*f*
- Tumors
 - glomus, 186*f*
 - Koenen's, 437
 - malignant appendage, 289
- Tungiasis, 823, 825, 825*f*
- ## U
- Ulcers, 1014*f*
 - aphthous, 976–977, 977*f*
 - Bairnsdale, 668–669, 669*f*
 - Buruli, 668–669, 669*f*
 - decubitus, 474–477, 475*f*–476*f*
 - leg. *See* Leg ulcers
 - Martorell's, 470, 471*f*
 - pressure, 474–477, 475*f*–476*f*
- Ulcus molle, 901–904
- Urticaria. *See* Angioedema and urticaria
- ## V
- Vaccines, drug reaction to, 556
- Valley fever, 743–744, 745*f*
- Varicella-zoster virus (VZV) infections, 800–819
 - epidemiology, 800
 - herpes zoster (HZ), 805–808, 807*f*, 809*f*
 - in HIV disease, 925
 - immunocompromised host, 812–816, 813*f*, 815*f*, 817*f*
 - laboratory examinations, 801–802
 - pathogenesis, 800
 - varicella, 801–804, 803*f*
- Varicose veins, 462, 463*f*, 467
- Variegate porphyria, 242–244, 243*f*, 244*t*
- Vascular hamartomas, 179
- Vascular insufficiency, skin signs of, 452–477
 - atherosclerosis, atheroembolization, and arterial insufficiency, 452–457

- chronic venous insufficiency, 462–467
 leg ulcers, 468–473
 pressure ulcers, 474–477
 thrombophlebitis and deep venous thrombosis, 458–461
- Vascular spider, 182*f*
- Vasculitis, 381–396
 giant cell arteritis, 390–391, 391*f*–392*f*
 hypersensitivity vasculitis, 381–384, 382*f*–383*f*
 nodular, 395, 396*f*
 polyarteritis nodosa, 384–386, 385*f*
 Schönlein-Henoch purpura, 384
 urticarial vasculitis, 393–394, 394*f*
 Wegener's granulomatosis (WG), 386–389, 387*f*–389*f*
- Venereal warts. *See* Human papillomavirus, sexually transmitted
- Venous lake, 180*f*
- Verruca, 760–762, 761*t*, 762*f*–763*f*, 765*f*
- Vesicle, 1011*f*–1012*f*
- Viral infections of skin and mucosa, 754–819
 herpesviruses. *See* Human herpesviruses (HHV)
 human papillomavirus infections. *See* Human papillomavirus infections
 infectious exanthems, 766–780
 erythema infectiosum, 778–780, 779*f*–780*f*
 hand-foot-and-mouth disease (HFMD), 776–778, 777*f*
 measles, 773–774, 775*f*
 overview, 766–767, 767*f*–769*f*
 rubella, 770–771, 771*f*–772*f*
 poxvirus infections, 754–759
 human orf, 758, 759*f*
 milker's nodules, 758, 759*f*
 molluscum contagiosum, 754–757, 756*f*–757*f*
 varicella-zoster virus (VZV). *See* Varicella-zoster virus infections
- Vitamin C deficiency, 428–429, 429*f*
- Vitiligo, 312–320, 313*t*, 314*f*–315*f*, 317*f*, 319*f*, 321*f*
 anogenital, 990, 990*f*
 differential diagnosis, 315–316
 distribution, 314–315, 314*f*
 repigmentation, 317*f*, 318–320, 321*f*
- Vitiligo universalis, 315, 319*f*
- Vulvar intraepithelial neoplasia, 869
- Vulvar melanosis, 988, 989*f*
- Vulvitis, 718, 719*f*
- W**
- Waldenström's macroglobulinemia, 504
- Warfarin-induced necrosis, 549, 549*f*
- Warts
 epidermodysplasia verruciformis, 762
 management, 764
 verruca plana (flat warts), 761–762, 765*f*
 verruca plantaris (plantar warts), 761–762, 765*f*
 verruca vulgaris (common warts), 761–762, 762*f*–763*f*
- Water-associated infections and infestations, 848–850, 848*t*, 849*f*–850*f*
- Wegener's granulomatosis (WG), 386–389, 387*f*–389*f*
- Wen, 188*f*
- Wheal, 1010*f*
- Wickham's striae, 114, 115*f*, 119*f*, 981, 981*f*
- Wood's lamp, 1015
- X**
- X-linked ichthyosis (XLI), 74–75, 75*f*
- Xanthelasma, 445, 446*f*
- Xanthelasma palpebrarum, 445, 446*f*
- Xanthoma striatum palmare, 450, 450*f*
- Xanthoma tendineum, 447, 447*f*
- Xanthoma tuberosum, 448, 448*f*
- Xanthomas, 444–450, 444*t*, 446*f*–450*f*
 eruptive, 449, 449*f*
- Z**
- Zidovudine-induced pigmentation, 566
- Zinc deficiency, 430–431, 431*f*
- Zoster sine zoster, 805

Recognize these skin alterations during the routine physical examination

(Numbers in parentheses refer to pages where disorder is discussed.)



Recognize these skin alterations during the routine physical examination

(Numbers in parentheses refer to pages where disorder is discussed.)

